Valuation: SOPHiA GENETICS SA

Market Cap 536M 464M 433M 398M 752M 51B 760M 5.09B 2B 25.52B 2.01B 1.97B 84.51B P/E 2026 *
-6.8x
P/E 2027 * -10x
Enterprise Value 536M 464M 433M 398M 752M 51B 760M 5.09B 2B 25.52B 2.01B 1.97B 84.51B EV / Sales 2026 *
5.65x
EV / Sales 2027 * 4.58x
Free-Float
77.18%
Yield 2026 *
-
Yield 2027 * -
1 day+0.46%
1 week+8.43%
Current month+10.66%
1 month+15.88%
3 months+28.57%
6 months+34.33%
Current year+39.18%
1 week 4.8
Extreme 4.8
5.45
1 month 4.74
Extreme 4.74
5.7
Current year 3.46
Extreme 3.46
5.7
1 year 3.34
Extreme 3.34
5.7
3 years 2.08
Extreme 2.08
5.7
5 years 2.08
Extreme 2.08
5.7
10 years 2.08
Extreme 2.08
5.7
Manager TitleAgeSince
Chief Executive Officer 46 01/07/2026
Director of Finance/CFO 64 05/11/2024
Chief Tech/Sci/R&D Officer - 10/01/2022
Director TitleAgeSince
Chairman 47 22/06/2026
Director/Board Member 57 01/06/2014
Chairman 61 01/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.92%+8.43% - - 536M
+0.78%+2.69%-24.14%+8.42% 34.68B
-1.19%+10.76%-44.32%+150.58% 13.28B
+0.52%-3.51%-23.35%+64.15% 5.44B
-0.40%+8.51% - - 2.34B
+1.47%+10.78% - - 1.86B
+0.05%-10.22%+21.87%-42.80% 1.69B
-2.21%+0.68%-37.57% - 1.04B
+4.52%+7.69%+35.48%+115.89% 913M
-0.27%+8.85%-38.09%-48.82% 847M
Average +0.37%+4.04%-15.73%+41.24% 6.9B
Weighted average by Cap. +0.28%+3.80%-26.86%+46.31%

Financials

2026 *2027 *
Net sales 94.92M 82.21M 76.63M 70.48M 133M 9.03B 135M 901M 353M 4.52B 356M 349M 14.96B 117M 101M 94.58M 86.99M 164M 11.14B 166M 1.11B 436M 5.57B 440M 430M 18.46B
Net income -72.67M -62.94M -58.67M -53.96M -102M -6.91B -103M -689M -271M -3.46B -273M -267M -11.45B -49.83M -43.16M -40.23M -37M -69.85M -4.74B -70.63M -473M -186M -2.37B -187M -183M -7.85B
Net Debt - -
Logo SOPHiA GENETICS SA
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Employees
415
Date Price Change
06/08/26 5.400 -0.92%
05/08/26 €5.450 +10.77%
04/08/26 €4.920 -1.20%
03/08/26 €4.980 +2.05%
31/07/26 €4.880 -2.01%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.300USD
Average target price
9.750USD
Spread / Average Target
+54.76%

Quarterly revenue - Rate of surprise